Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) Antibody [TIGIT/3106]

In Stock
Catalog Number Formulation Size Price
201633-MSM6-B1
Purified Ab conjugated to Biotin
0.5ml at 100ug/ml
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy.

Product Properties & Targets

Antibody Type
Host
Mouse
Applications
Species Reactivity
Research Areas
Isotype / Light Chain
IgG2b /
Cellular Localization
Cell membrane
Gene Name
Positive Control
Human tonsil or prostate carcinoma
Immunogen
Recombinant fragment (around aa 22-141) of human TIGIT protein (exact sequence is proprietary)
Alternate Names
T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain containing 9 (VSIG9); V-set and transmembrane domain containing 3 (VSTM3); Washington University Cell Adhesion Molecule (WUCAM)

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
TIGIT/3106
Chromosome Location
3q13.31
Mol. Weight of Antigen
26kDa

Functions

  • Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Key References

  • Dougall WC, et al. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276: 112-120.
  • Johnston et al., The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function, CancerCell (2014).

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK